Search - tctmd.com

Displaying 21 - 40 of 65

Sort: Relevancy | Date

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Shelley Wood

December 23, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Shelley Wood

October 29, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

Alirocumab Price Slashed in Deal With Express Scripts

Michael O'Riordan

May 03, 2018

News Daily News

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Michael O'Riordan

October 28, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

Advertisement

British Medical Groups Express Concern About Inclisiran Rollout

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Heterozygous FH Diagnosed Late, Remains Undertreated

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Passes on Inclisiran, Citing Manufacturing Site Problems

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

CHD Mortality Significantly Elevated in Patients With Severe FH

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Final Phase III Bempedoic Acid Trial Proves Positive for LDL-Lowering

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Alirocumab Price Slashed in Deal With Express Scripts

FH Screening Started at Time of Childhood Immunization Feasible and Effective

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content